Clinical results and risk factors of proton and @entity505 ion therapy for XXXX .

@entity1 @entity137 @entity5 @entity505 @entity157
BACKGROUND: The objective of this study was to evaluate the clinical outcome of proton and @entity505 ion therapy for @entity157 ( @entity157 ). METHODS: In total, 343 consecutive @entity1 with 386 @entity5 , including 242 @entity1 (with 278 @entity5 ) who received proton therapy and 101 @entity1 (with 108 @entity5 ) who received @entity505 ion therapy, were treated on 8 different protocols of proton therapy (52.8-84.0 gray equivalents [GyE] in 4-38 fractions) and on 4 different protocols of @entity505 ion therapy (52.8-76.0 GyE in 4-20 fractions). RESULTS: The 5-year local control and overall survival rates for all @entity1 were 90.8% and 38.2%, respectively. Regarding proton and @entity505 ion therapy, the 5-year local control rates were 90.2% and 93%, respectively, and the 5-year overall survival rates were 38% and 36.3%, respectively. These rates did not differ significantly between the 2 therapies. Univariate analysis identified @entity5 size as an independent risk factor for local recurrence in proton therapy, @entity505 ion therapy, and in all @entity1 . Multivariate analysis identified @entity5 size as the only independent risk factor for local recurrence in proton therapy and in all @entity1 . @entity1 -Pugh classification was the only independent risk factor for overall survival in proton therapy, in @entity505 ion therapy, and in all @entity1 according to both univariate and multivariate analyses. No @entity1 died of treatment-related @entity137 . CONCLUSIONS: Proton and @entity505 ion therapies for @entity157 were comparable in terms of local control and overall survival rates. These therapies may represent innovative alternatives to conventional local therapies for @entity157 .
